We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
-16.32%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
AUM
$592M
AUM Growth
-$251M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$310M 52.3%
4,632,149
FHTX icon
2
Foghorn Therapeutics
FHTX
$285M
$118M 19.94%
12,674,120
SANA icon
3
Sana Biotechnology
SANA
$885M
$104M 17.57%
25,001,856
OMGA
4
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$35.7M 6.02%
29,225,579
MCRB icon
5
Seres Therapeutics
MCRB
$48.1M
$21.9M 3.7%
1,155,852
SYRS
6
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.78M 0.47%
1,293,849

Similar funds

Flagship Pioneering's Q3 2024 Portfolio in Review

As of Q3 2024, Flagship Pioneering held 6 positions worth $592M, down 30% from $843M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2024: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's ten largest holdings make up 100% of its $592M portfolio in Q3 2024.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q3 2024.
  • Flagship Pioneering's portfolio value fell 30% quarter-over-quarter to $592M.

Based on Flagship Pioneering's 13F filing for Q3 2024, filed 14 Nov 2024.